Cimalgex (3 - 4 kg)
Active substance
ATC code
Species
Dogs
Indications
For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri- operative pain due to orthopaedic or soft tissue surgery, in dogs.
Dose to be administered and administration route
Oral use.
The recommended dose of cimicoxib is 2 mg per kg bodyweight, once daily. The following table is presented as an example of how the tablets and tablet parts could be used in order to reach the recommended dose.
|
Bodyweight kg |
8 mg |
30 mg |
80 mg |
|
2 |
1/2 |
||
|
3 |
1 |
||
|
4 |
1 |
||
|
5 |
1/3 |
||
|
6 |
1+1/2 |
||
|
7‐8 |
2 |
||
|
9‐11 |
2+1/2 |
||
|
12 |
3 |
||
|
13‐17 |
1 |
||
|
18‐22 |
1/2 |
||
|
23‐28 |
1+2/3 |
||
|
29‐33 |
2 |
||
|
34‐38 |
2+1/3 |
||
|
39‐43 |
1 |
||
|
45‐48 |
3 |
||
|
49‐54 |
1+1/4 |
||
|
55‐68 |
1+1/2 |
The choice of the most suitable tablet type or tablet parts is left to the discretion of the veterinarian based on the circumstances in each case, without leading to important over- or underdosing.
Treatment duration:
• Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian.
• Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinarian.
Cimalgex tablets can be administered with or without food. The tablets are flavoured and studies (in healthy Beagle dogs) show they are likely to be taken voluntarily by most dogs.
Adverse reactions
Mild and transient gastro-intestinal disorders (vomiting and/or diarrhoea) were very commonly reported.
On rare occasions, serious gastrointestinal disorders such as haemorrhage and ulcer formation have been noted. Other adverse reactions including anorexia or lethargy or polyuria and/or polydipsia may also be observed on rare occasions.
In very rare cases, increases in renal biochemistry parameters were noted. Furthermore, in very rare cases, renal failure has been reported. As for any long term NSAID treatment, renal function should be monitored.
If any observed adverse effect persists after stopping treatment, the advice of a veterinarian should be sought.
If adverse reactions such as persistent vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy or worsening of renal or hepatic biochemistry parameters occur, use of the product should be discontinued and appropriate monitoring and/or treatment should be put in place. Severe gastrointestinal and renal adverse events may be fatal.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
Dispensing
POM-V
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 06462/5002 |
| EAN | 3605874255982 |
